Impact of insurance status on survival in neuroendocrine tumors: A multi-institutional Study from the U.S. Neuroendocrine Study Group.

Authors

null

Paula Marincola Smith

Vanderbilt University Medical Center, Nashville, TN

Paula Marincola Smith , Alexandra G Lopez-Aguiar , Mary Dillhoff , Eliza W Beal , George A. Poultsides , Eleftherios Makris , Flavio G. Rocha , Angelena Crown , Clifford Cho , Megan Beems , Emily Winslow , Victoria Rendell , Bradley A. Krasnick , Ryan Fields , Shishir Maithel , Kamran Idrees

Organizations

Vanderbilt University Medical Center, Nashville, TN, Emory University Winship Cancer Institute, Atlanta, GA, Ohio State University Comprehensive Cancer Center, Columbus, OH, Stanford University School of Medicine, Stanford, CA, Virginia Mason Medical Center, Seattle, WA, Virginia Mason Hospital and Medical Center, Seattle, WA, University of Michigan, Ann Arbor, MI, University of Wisconsin Carbone Cancer Center, Madison, WI, University of Wisconsin School of Medicine and Public Health, Madison, WI, Washington University School of Medicine in St. Louis, St. Louis, MO

Research Funding

Other

Background: Insurance status predicts access to medical care in the United States. Previous studies show uninsured and government insured patients have worse outcomes than those with private insurance. However, the impact of insurance status on survival in patients with Gastrointestinal Neuroendocrine Tumors (GI-NETs) is unclear. We evaluate the association between insurance status and survival in patients with GI-NETs. Methods: Our analysis includes 2022 patients who had surgical resection of GI-NETs at 8 institutions in the U.S. Neuroendocrine Study Group. Patients were categorized based on insurance as private (PI), government (GovI) or uninsured (UI). Factors associated with insurance status were assessed by uni- and multi-variate analysis. Primary endpoint was overall survival. Results: Patient demographics between the insurance categories were similar in ECOG performance status and tumor size at presentation. GovI patients had a higher median age than PI or UI (66 vs. 54 vs. 56 years respectively; p<0.01). Uninsured patients were more likely African American (21.5%) or Latino (5%) compared to PI (11.5%, 2%) or GovI (15%, 2%) (p<0.01). The UI group had a higher proportion of patients who underwent no surveillance imaging post-operatively (39%) compared to PI (26%) and GovI patients (26%) but this was not statistically significant (p=0.15). There was no difference in operative intent (curative vs. palliative) between groups (p=0.2). Five-year overall survival was 86% for PI, 82% for GovI, and 73% for UI patients (p<0.01). On multivariate regression analysis, being uninsured was independently associated with reduced survival when controlling for ASA Class, ECOG, race, tumor location, neoadjuvant and adjuvant chemotherapy, Somatostatin analog, or radiation therapy (HR 1.39, p = 0.012). Conclusions: This is the first systematic analysis of insurance status’s association with overall survival in GI-NET patients. Our analysis shows uninsured or government insured patients have shortened survival compared to the privately insured. The disparity is likely underrepresented in this study, as we examined only patients who underwent surgical resection.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 371)

DOI

10.1200/JCO.2018.36.4_suppl.371

Abstract #

371

Poster Bd #

H8

Abstract Disclosures

Similar Abstracts

First Author: Benjamin D. Mercier

First Author: Hanna Kakish

Abstract

2023 ASCO Annual Meeting

Specialty cancer care and survival in AYA ALL: A U.S. multi-state analysis.

First Author: Lori S. Muffly